

सं. / No. 50014/03/2020-CDN  
भारत सरकार / Government of India  
रसायन एवं उर्वरक मंत्रालय / Ministry of Chemicals and Fertilizers  
औषध विभाग / Department of Pharmaceuticals  
\*\*\*\*\*

223ए, शास्त्री भवन, नई दिल्ली  
223A, Shastri Bhawan, New Delhi  
Dated: 19 December, 2023

**OFFICE MEMORANDUM**

**Subject: Monthly Summary Report in respect of Department of Pharmaceuticals for the month of November, 2023-reg.**

The undersigned is directed to circulate herewith a copy of the Monthly Summary pertaining to the Department of Pharmaceuticals for the month of November, 2023 for information.



(S.U. Ansari)

Under Secretary to the Govt. of India  
Tel. 011-23387920

To,

1. All members of Council of Ministers.
2. Vice Chairman, NITI Aayog, Yojana Bhawan, New Delhi.
3. The Principal Information Officer, M/o Information and Broadcasting, Shastri Bhawan, New Delhi.

Copy to:

1. Secretaries to the Govt. of India, All Ministries/Department.
2. The Chairman, UPSC, Shahajahan Road, New Delhi-110069.
3. Secretary to President of India (Rashtrapati Ke Sachiv), Rashtrapati Bhawan, New Delhi-110004.
4. Secretary to Vice- President of India (Uprashtrapati Ke Sachiv), New Delhi-110004.
5. PS to Prime Minister of India, South Block, New Delhi-110004.
6. Director, Cabinet Secretariat, Rashtrapati Bhawan, New Delhi-110004.
7. Sr. PPS to Secretary (Pharma).
8. Director (NIC), Department of Pharmaceuticals, Shastri Bhawan, New Delhi.

**Ministry of Chemicals & Fertilizers**  
**Department of Pharmaceuticals**

**1. Important policy decisions taken and major achievements during the month of November 2023:**

**A. National Institutes of Pharmaceutical Education & Research (NIPERs):**

***Schemes:***

The Cabinet approved the Scheme for Promotion of Research and Innovation in Pharma-Med Tech (PRIP) with an outlay of Rs.5000 crore for a five-year period from 2023-24 to 2027-28. Launched by the HMCF on September 26, 2023, operational guidelines of the scheme have been uploaded on the Department website. The application for Request for Proposal from CPSEs/Public Financial Institutions to work as a Project Management Agency (PMA) for PRIP Scheme was invited, with the submission deadline extended to 30<sup>th</sup> November 2023.

***Research Papers, Patents and MoUs:***

- Out of 678 research papers published during the current financial year, 82 papers have been published in the month of November 2023.
- Out of 33 Patents filed during the current financial year, 2 patents were filed in the month of November 2023.
- Out of the 26 MoUs signed during the current financial year, 2 MoUs have been signed in the month of November 2023.

***Workshops/Seminars/Training and other events:***

- A DBT project entitled “Therapeutic Leads for Pain from Conus Peptides of Indian Marine Coast” was granted to NIPER-Hyderabad for 3 years for Rs.89,58,600.
- NIPER Hyderabad celebrated World Antimicrobial Resistance (AMR) Awareness Week #WAAW 2023.
- NIPER-Mohali organized Workshop on “Pharmaceutical Statistics, Design of Experiment control charts, lean Methodologies, process improvement, shelf life extrapolation” on November 25, 2023.
- NIPER-Mohali invited talk on “Genotoxic Azido impurities in Drug Substances: Concern for Pharma Industry on November 25, 2023.
- NIPER-Mohali organized Seminar ~~invited~~ on “Chemistry and Biology challenges in Drug Discovery and Development on November 23, 2023.
- NIPER-Mohali organized Talk on “Innovation and Entrepreneurship Start-up: Technology vs. Legal vs. Business perspective” on November 28, 2023.
- NIPER-Mohali organized One Week Training on high performance liquid Chromatography (HPLC) on from October 30- November 3, 2023.
- NIPER-Guwahati organized experts’ talks on needs, Relevance and Facets of Entrepreneurship Development and Startups on November 9, 2023.
- NIPER-Guwahati organized event on Start-Up in Knowledge Economy on November 10, 2023.
- NIPER-Raebareli organised 3 Days Placement Readiness Workshop on 23<sup>rd</sup> November 2023 for students.
- NIPER-Raebareli celebrated the 62<sup>nd</sup> National Pharmacy Week 2023 (19 November to 25 November 2023) with the theme "Join Pharmacists to Ensure Patients’ Safety’.

## B. National Pharmaceutical Pricing authority (NPPA):

(i) During the month, prices fixed for 33 new drugs in the 118<sup>th</sup> Authority meeting held on 08.11.2023. These were notified vide S.O. No. 4885 (E) dated 10.11.2023. Also, the ceiling prices of 9 drugs revised under NLEM 2022 in the Authority Meeting held on 8.11.2023 and these were notified vide S.O. No. 4886(E) dated 10.11.2023. The details of drug prices fixed during the financial year 2023-2024 are as under:

S. No.	Prices fixed/ Notified under Revised Schedule I (NLEM 2022)	During the month of 1 <sup>st</sup> November, 2023 to 30 <sup>th</sup> November 2023	Cumulative from 1 <sup>st</sup> April, 2023 to 30 <sup>th</sup> November 2023
1.	Retail Price of 'New Drug'	33	246
2.	(i) Fixation of ceiling Price under revised scheduled-I (NLEM 2022) of DPCO, 2013	9	49
	(ii) Fixation of ceiling price with special features under scheduled - I (NLEM 2022) of DPCO, 2013	0	2
	(iii) Exemption under para 32 of DPCO, 2013 (NLEM 2022)	0	3

(ii) On the basis of Monitoring & Enforcement activities, twenty-nine (29) Preliminary Notices (PN) were issued.

(iii) As a result of enforcement activities, during the month of November 2023, **Rs.5,98,03,177/-** (Rupees Five Crore Ninety-Eight Lakh Three Thousand One Hundred Seventy-Seven only) was received towards overcharged amount.

(iv) NPPA through Price Monitoring and Resource Units (PMRUs) in the States/UTs conducted 4 market surveys in November 2023 to assess the availability of drugs.

(v) NPPA is encouraging use of e-office to reduce the use of paper and in line with this effort, 139 new e-files were opened during the month.

## C. International Cooperation:

(i) Ms. Gayatri Nair, Economic Advisor, DoP participated as a panelist in the second World Local Production Forum (WLPF) organized by the World Health Organisation at The Hague, The Netherlands from **November 6 to 8, 2023** and for the session titled "*Tackling bottlenecks of Regional Production*". The presentation highlighted the essential ingredients required for a successful regional production initiative and the major interventions by GoI, especially Department of Pharmaceuticals in supporting all stages of product development from ideation to commercialization

(ii) Officials of Department of Pharmaceuticals participated in the Seminar on **6<sup>th</sup> November 2023** on the theme of "Unlocking Trade for Growth", "Preparing for the Future of Work" and "Advancing Financial Inclusion." organized by Department of Commerce.

(iii) Dr. Rahul Gupta, Director, US Office of National Drug Control Policy (ONDCP); Mr. John Unger Special Advisor; and Mr. Gary Applegarth, First Secretary, US Embassy, and official from MEA met Secretary, Pharmaceuticals on **20<sup>th</sup> November 2023**, wherein ongoing work undertaken to mitigate drug abuse, diversion of illicit chemicals/drugs, were discussed.

(iv) Economic Advisor, DoP participated in the 19th Session of India- Switzerland Joint Economic Commission (JEC) on **24<sup>th</sup> November 2024**, Geneva through virtual mode and spoke about

possible collaboration with NIPERs and investment opportunities in Pharma and Medical Devices sector.

(v) Mr Bart Ooijen, Counsellor of Health, Welfare, and Sport and Ms Ravleen Pal, Deputy Head of Economic Section, Embassy of Netherlands met Economic Advisor, DoP on **28<sup>th</sup> November 2023** wherein possible cooperation in bilateral investments, capacity building with NIPERs and strengthening of supply chain between were discussed.

(vi) Dr. Mohamad Peykanpur- Hon'ble Director General- Ministry of Health of I.R of Iran, Mr. Mohammadreza Abedi- Deputy Director General, Ministry of Health of I.R of Iran, Mr. Naser Hirad- Deputy Secretary, Ministry of Health of I.R of Iran, Mr. Mostafa Goharifar- Economic Counselor at Embassy of Islamic Republic of Iran, New Delhi, Mr. Abolfazl Rohanifard- Second Secretary at Embassy of Islamic Republic of Iran, New Delhi met Economic Advisor, DoP on **30<sup>th</sup> November, 2023**, wherein possible collaboration with NIPERs and investment opportunities in Pharma and Medical Devices sector were discussed.

#### **D. Schemes:**

##### **(i) Status of Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP):**

Number of PMBJP Kendras functional		Sales under PMBJP at MRP Value in Rs. Crore and saving to common man during the month of November 2023		Product basket (As on 30.11.2023)		Sale of Suvidha Sanitary Napkins @ Rs. 1/- per pad during the month November, 2023	Incentive provided in the month November, 2023
November 2023	Cumulative	Sale	Saving	Medicines	Surgical	1.27 crore	Rs.3.24 crore
	(As on 30.11.2023)	In Rs. (Cr.)	In Rs. (Cr.) (Approx.)	In Rs. (Cr.)	In Rs. (Cr.) (Approx.)		
26	10006	122.37	611.85	1965	293		

##### **(ii) Status of PLI Schemes**

S. No.	Name of Scheme		Total No. of Application Received	Total no. of applications approved till end November, 2023
1.	Production Linked Incentive Scheme for Bulk Drug (Last EC Meeting held on 04.10.2023 on PLI Bulk Drugs)	Round 1	215	38
		Round 2	24	07
		Round 3	09	02
		Round 4	01	01
		<b>Total</b>	<b>249</b>	<b>48</b>
2.	Production Linked Incentive (PLI) Scheme for Medical Device (Last EC Meeting held on 04.10.2023 on Medical Devices)	Round 1	28	11
		Round 2	14	08
		Round 3	18	05
		Round 4	04	02
		<b>Total</b>	<b>64</b>	<b>26</b>

3	Production Linked Incentive (PLI) Scheme for Pharmaceuticals	278	55
---	--	-----	----

(iii) The Actual progress made as on September 2023 under the PLI Schemes are as follows:

Details as on September 2023	PLI Bulk Drugs	PLI Medical Devices	PLI Pharmaceuticals
Actual Investment (Rs. in Cr.)	3062.69	879.42	25104
Actual Production (Rs. in Cr.)	817.33	3251.76	109745
Actual Employment (No. of persons)	2777	4546	56171
Project Commissioned	27	16	261 manufacturing locations

2. Important policy matters held up on account of prolonged inter-ministerial consultations:

NIL

3. No. of cases of 'sanction for prosecution' pending for more than three months:

NIL

4. Particulars of cases in which there has been a departure from the Transaction of Business Rules or established policy of the Government:

NIL

5. Status of ongoing Swachhata Abhiyan (progress under Special Campaign):

NIL

6. Status of Rationalization of Autonomous Bodies:

Completed

7. Information on the specific steps taken by the Ministry/Department for utilization of the Space Technology based tools and applications in Governance and Development:

NIL

8. Vacancy position of senior level appointments in the Ministry/Department, including Autonomous Bodies/PSUs:

(i) Department of Pharmaceuticals:

S. No.	Name of the posts	Sanctioned Strength	In-position	Vacancy	Group
1	JS	02	01	01	A
2	Director/DS	07*	05	02	A
3	Principal Private Secretary	02	00	02	A
4	Under Secretary	10	09	01	A

5	Section Officer	16	12	04	B
	<b>Total</b>	<b>27</b>	<b>19</b>	<b>8</b>	

\* It includes newly sanctioned one post of Indian Economic Service.

**(ii) Public Sector Undertakings:**

**(a) Karnataka Antibiotics & Pharmaceuticals Limited (KAPL):**

S. No.	Designation	Vacant Positions
1	Senior Manager	06
2	Deputy General Manager	00
3	General Manager	06
	<b>Total</b>	<b>12</b>

**(b) Hindustan Antibiotics Limited (HAL) (under strategic sale):**

S.No.	Designation	Vacant Positions
1	CGM	03
2	GM	03
3	DGM	12
4	Manager	20
	<b>Total</b>	<b>38</b>

**(c) Bengal Chemicals & Pharmaceuticals Limited (BCPL) (under strategic sale):**

S.No.	Designation	Vacant Positions
1	Manager (Legal)	01
2	DGM (Marketing)	01
3	Sr. Manager (Purchase)	01
4	DGM (Finance)	01
5	Factory Head (DGM/AGM)	02
6	AGM (QA/QC)	01
	<b>Total</b>	<b>07</b>

**(d) Indian Drugs & Pharmaceuticals Limited (IDPL) : NIL**

**(e) Rajasthan Drugs & Pharmaceuticals Limited (RDPL) : NIL**

**9. List of cases in which ACC directions have not been complied with:**

NIL

**10. Details of FDI proposals cleared during the month and status of FDI proposals awaiting approval in the Ministry/Department:**

(i)	Pending at beginning of the month	10
(ii)	Received during the month	3
(iii)	Disposed of during the month	0
(iv)	Pending at end of the month	13

FDI inflow approved during this month: NIL.